Castuner

AML Hub

Scientific Education Support

The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Site do podcast

Ouça no seu app

Episódios

45 episódios

  1. The role of combination strategies in the treatment of FLT3-mutated acute myeloid leukemia 27:25
  2. Targeting menin: A paradigm shift in acute myeloid leukemia therapy 34:20
  3. FLT3 inhibitors in AML: Current clinical landscape and key insights from trials 4:30
  4. Future directions for FLT3 inhibitors in AML treatment 4:00
  5. Key questions in FLT3-mutated AML, and ongoing research to address these 5:15
  6. Menin inhibitors in AML: Where are we now, and where are we going? 30:18
  7. Managing side effects of menin inhibitors in clinical practice 7:52
  8. Mechanisms and rationale for menin inhibitor combination strategies in AML 4:20
  9. Treatment decisions in AML: Personalizing care with FLT3 inhibitor therapy 32:30
  10. What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML? 5:09
  11. Symposium | Understanding the differences between FLT3-ITD and -TKD mutations in AML: Q&A 7:10
  12. Symposium | Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations 14:19
  13. Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations 20:09
  14. Symposium | FLT3 mutations in AML: Types, prevalence, and clinical significance 16:43
  15. ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety 8:24
  16. ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction in fit adults with ND AML 7:20
  17. Clinical research round-up: Current and emerging treatments for IDH1-mutated AML 4:41
  18. Menin inhibitors in AML: Bridging the gap between trial data and clinical practice 7:01
  19. Addressing uncertainty in patient selection for transplant in AML 23:19
  20. Integrating menin inhibitors into the treatment landscape of AML: Future directions 5:33
  21. Know AML webinar | Closing remarks and Q&A 9:49
  22. Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward? 9:33
  23. Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey 27:09
  24. Know AML webinar | What are mutations, and why do they matter in AML? 13:08
  25. “How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy 5:59
  26. CPX-351 as first-line treatment in AML: Real-world data 16:36
  27. What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​? 13:06
  28. What were your highlights from ASH 2023? 3:36
  29. What are the challenges associated with CAR T-cell therapy in patients with AML? 9:19
  30. How might the MORPHO trial of gilteritinib impact clinical practice? 7:27
  31. Risk stratification and guidelines in AML management 11:49
  32. How are new fludarabine conditioning combinations impacting transplant outcomes? 6:04
  33. Should pre-transplant MRD be used to guide treatment in AML? 6:08
  34. Should pre-transplant MRD be used to guide treatment in AML? 13:54
  35. Should pre-transplant MRD be used to guide treatment in AML? 5:03
  36. Can HMA maintenance therapy improve eligibility for HSCT? 5:22
  37. ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML? 16:07
  38. Venetoclax combinations in mutant AML subtypes: IDH1/2 6:42
  39. Venetoclax combinations in mutant AML subtypes podcast: FLT3 12:07
  40. Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML 8:38
  41. How close are we to offering treatment tailored to mutational profile? 5:54
  42. Approaches and emerging therapies for TP53 AML 14:29
  43. How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease 24:34
  44. Can CD47 antibody therapy be safely used for AML and MDS? 14:34
  45. How does the type of prior treatment affect the risk of therapy-related myeloid neoplasms? 20:15